Author Login

Correspondence to Author: Sephen Tavis, 

Oanal T. Cilson, Department of Orthopedic, Bone and Joint Institute at Hartford Hospital.

Introduction : Proximal femur fragility fractures continue to be a leading cause of morbidity and mortality in the United States and around the world. At our institution, a fragility fracture is defined as any fracture in a patient over 50 that follows a fall from a standing height or similar low energy mechanism, though definitions differ depending on the center [1]. Globally, there were 10 million fragility hip fractures in 2019, and by 2050, that figure is predicted to almost treble [2,3]. Following hip fractures, loss of functional status and walking ability is almost certain, and many patients also lose their capacity for independent living. For white women, the lifetime risk of hip fracture is 1 in 6, while the chance of breast cancer is 1 in 9. [4] At 30 days, mortality rates following hip fractures approach 10% and rise to almost thirty percent after a year.

Undoubtedly, there are many different factors contributing to these poor results, including prolonged immobility, injury and surgery complications, and low baseline health status. Many studies have been conducted with the goal of reducing mortality and poor outcomes, with a particular emphasis on accelerating the surgical treatment of fragility hip fractures. Patients with hip fractures who receive surgery within 48 hours have fewer problems, a shorter hospital stay, and a reduced death rate, according to extensive research.

Citation:

Sephen Tavis. Tranexamic acid and Reducing Blood Transfusions in the Fragility Hip Fracture Population: A Practical Application of Fundamental Ideas. The American Journal of Hematology 2024.